DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Mild Cognitive Impairment - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Mild Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mild Cognitive Impairment and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Mild Cognitive Impairment Overview
- Therapeutics Development
- Pipeline Products for Mild Cognitive Impairment - Overview
- Pipeline Products for Mild Cognitive Impairment - Comparative Analysis
- Mild Cognitive Impairment - Therapeutics under Development by Companies
- Mild Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes
- Mild Cognitive Impairment Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Mild Cognitive Impairment - Products under Development by Companies
- Mild Cognitive Impairment - Products under Investigation by Universities/Institutes
- Mild Cognitive Impairment - Companies Involved in Therapeutics Development
- AbbVie Inc.
- AgeneBio Inc.
- Avraham Pharmaceuticals Ltd.
- CereSpir Incorporated
- D-Pharm Ltd.
- Eisai Co., Ltd.
- Eli Lilly and Company
- Ensol Biosciences Inc.
- Genzyme Corporation
- Nanotherapeutics, Inc.
- Neuron Biopharma SA
- Octapharma AG
- Sage Therapeutics, Inc.
- Suven Life Sciences Ltd.
- Takeda Pharmaceutical Company Limited
- Therapix Biosciences Ltd
For more information visit http://www.researchandmarkets.com/research/9dphjg/mild_cognitive